Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial

Overview of attention for article published in Liver International, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 1 X user

guideline: 2 clinical guideline sources

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 1 X post from an account with 9,635 followers.

Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial https://t.co/vyCKNOjlg5

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.